FinanceLatest NewsUAE

Dubai Explores Future of Mainstream Anti-Ageing Treatments

Dubai’s Next Generation Medicine 2026 congress opened on Saturday, November 7, bringing together global experts to examine whether anti-ageing therapies could eventually become a standard part of mainstream healthcare.

The congress features more than 70 speakers from over 20 countries, with discussions covering advances in regenerative medicine, artificial intelligence, biological-age testing and preventive healthcare.

The event comes as Dubai accelerates its ambitions to establish itself as a global centre for longevity medicine, following the launch of the Dubai Longevity Authority earlier this year.

Dr Jaffer Khan, Founder and CEO of AEON Clinic and Aesthetics International, said the industry is experiencing a major shift as more patients focus on preventing age-related diseases rather than seeking treatment after health conditions emerge.

Khan highlighted how patient priorities have evolved over the past 25 years, with consultations increasingly involving blood test results, wearable health data and questions about metabolic, hormonal and gut health, rather than focusing solely on aesthetic concerns.

Although longevity medicine has traditionally been associated with premium wellness clinics and experimental therapies, Khan expects preventive healthcare to become considerably more accessible before the end of the decade.

He said prevention-focused health assessments could become a routine component of mainstream healthcare within the current decade, moving beyond their traditional positioning as premium services.

Several longevity-related technologies are already being used in clinical settings, including genomic screening, advanced imaging, biomarker testing and continuous health monitoring.

However, the growing use of these technologies does not necessarily establish their effectiveness in slowing biological ageing, highlighting the need to distinguish between available medical tools and clinically proven treatments.

Khan cautioned that several regenerative and cellular therapies remain under investigation and require stronger clinical evidence before they can be introduced more widely into healthcare systems.

He described the industry’s progress as uneven, with some areas of longevity medicine closer to mainstream adoption than others, stressing the importance of distinguishing established advances from claims that still require scientific validation.

Held under the theme From Evidence to Adoption — Building the Clinic of 2030 Today, the congress aims to address these challenges by bringing together researchers, clinicians and industry leaders to explore how emerging longevity treatments can be integrated safely into healthcare systems.